Evidence map›Paper›PMID 16912916›Full record

ArticleClinical & experimental metastasis2006

The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.

Angèle Nalbandian, Daniel Djakiew

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Angèle NalbandianDepartment of Biochemistry and Molecular and Cellular Biology, Georgetown University Medical Center, Medical Dental Building, Washington, DC 20057-1436, USA.
Daniel Djakiew
Georgetown University Medical Center · US

Funding

NGF RECEPTOR REGULATION OF PROSTATE GROWTHR01DK052626 · NIDDK · GEORGETOWN UNIVERSITY · PI DJAKIEW, DANIEL · 1999 to 2006
$1.5M
NIDDK NIH HHS R01 DK 52626
6 · The paper itself

Abstract

The p75 neurotrophin receptor (p75(NTR)) has been characterized as a metastasis and tumor suppressor in prostate cancer. In order to investigate the mechanism(s) by which the p75(NTR) functions as a metastasis suppressor in prostate cancer cells, we characterized the ectopic expression of p75(NTR) on the urokinase plasminogen activator (uPA) and the type IV collagen matrix metalloproteinases (MMP-2 and MMP-9) in PC-3 human prostate cancer cells. Rank-order expression of p75(NTR) greatly reduced protein levels and enzymatic activities of uPA, MMP-2, and MMP-9 as shown by immunoblot and zymography analyses. Conversely, expression of the MMP-9 antagonist, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) exhibited an increase in protein levels with an increase in p75(NTR) levels, whereas TIMP-2 was not detected. Transient transfection with an inducible dominant negative antagonist Deltap75(NTR) rescued uPA, MMP-2, and MMP-9 protein levels and protease activities, and conversely suppressed TIMP-1 levels. Since p75(NTR) signal transduction occurs via the NFkappaB and JNK pathways, antagonism of signaling intermediates in these pathways, using dominant negative IKKbeta or dominant negative MKK-4, respectively, was shown to further decrease expression of uPA, MMP-2, and MMP-9 protein and enzymatic activity levels, and conversely up-regulate levels of TIMP-1. These results indicate that expression of uPA, MMP-2, MMP-9, and TIMP-1 are directly regulated by expression of p75(NTR) and its downstream signal transduction cascade. These results suggest that the metastasis suppressor activity of p75(NTR) is mediated, in part, by down-regulation of specific proteases (uPA, type IV collagenases) implicated in cell migration and metastasis.

Indexed as

Cell Line, TumorGene Expression Regulation, NeoplasticHumansMaleMatrix Metalloproteinase 2Matrix Metalloproteinase 9Matrix MetalloproteinasesNerve Tissue ProteinsProstatic NeoplasmsReceptors, Nerve Growth FactorTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinase-2TransfectionTumor Suppressor ProteinsUrokinase-Type Plasminogen ActivatorMatrix Metalloproteinase 2Matrix Metalloproteinase 9Matrix MetalloproteinasesNerve Tissue ProteinsNGFR protein, humanReceptors, Nerve Growth FactorTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinase-2Tumor Suppressor ProteinsUrokinase-Type Plasminogen Activator

Identifiers

PMID16912916
OpenAlexW2136880181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.